ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation ADCs August 2, 2023
Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours August 2, 2023
AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets August 2, 2023
Phase 3 Study of V940 (mRNA-4157) + KEYTRUDA initiated for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma August 2, 2023
Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS To Discontinue August 2, 2023
Ph 2 LOTIS-9 Trial of ZYNLONTA (loncastuximab tesirine-lpyl) and Rituximab in Unfit/Frail 1L DLBCL Patients to be discontinued August 2, 2023
Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization Announced August 2, 2023
UGN-102 Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials in NMIBC patients August 2, 2023
In CARES 310 trial, camrelizumab + rivoceranib statistically prolonged OS and PFS and improved ORR versus sorafenib in uHCC August 2, 2023
Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma August 2, 2023
Enhertu demonstrated clinically meaningful PFS and OS across multiple HER2-expressing advanced solid tumours in DESTINY-PanTumor02 Phase II trial August 2, 2023
Ph 3 KEYNOTE-756 Trial Met Primary Endpoint of pCR Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer August 2, 2023
FDA Grants Fast Track designation to IVS-3001 for the Treatment of Renal Cell Carcinoma August 2, 2023
EMA Approves Clinical Trial Application (CTA) for AVC-201 for the Treatment of R/R AML and other CD123 Hematological Malignancies August 2, 2023
CHMP Positive Opinion for JZP458 for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma August 2, 2023
FDA clears IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma August 2, 2023
European Commission Approves Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer August 2, 2023
